C([NH:5][S:6]([CH2:9][CH2:10][C:11]1[CH:16]=[CH:15][C:14]([NH:17][C:18]([C:20]2[N:21](COCC[Si](C)(C)C)[CH:22]=[C:23]([C:25]#[N:26])[N:24]=2)=[O:19])=[C:13]([C:35]2[CH2:40][CH2:39][CH2:38][CH2:37][CH:36]=2)[CH:12]=1)(=[O:8])=[O:7])(C)(C)C.CCO.C1(OC)C=CC=CC=1.[C:52]([OH:58])([C:54]([F:57])([F:56])[F:55])=[O:53]>C(Cl)Cl>[F:55][C:54]([F:57])([F:56])[C:52]([OH:58])=[O:53].[C:35]1([C:13]2[CH:12]=[C:11]([CH2:10][CH2:9][S:6](=[O:7])(=[O:8])[NH2:5])[CH:16]=[CH:15][C:14]=2[NH:17][C:18]([C:20]2[NH:21][CH:22]=[C:23]([C:25]#[N:26])[N:24]=2)=[O:19])[CH2:40][CH2:39][CH2:38][CH2:37][CH:36]=1To a solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide (as the prepared in previous step, 275 mg, 0.470 mmol) in DCM (5 mL), EtOH (140 μL), anisole (51 μL) and TFA (1.5 mL) were added. The resulting solution was stirred at RT for 6 h. An additional 0.35 mL of TFA was added and the resulting mixture was stirred at RT overnight. The reaction mixture was concentrated and the residue was subjected to RP-HPLC eluting with 20% to 100% CH3CN in 0.1% TFA/H2O over 20 min on a C18 column to afford the title compound (26.6 mg, 11%). 1H-NMR (DMSO-d6; 400 MHz): δ 9.72 (s, 1H), 8.31 (s, 1H), 7.85 (d, 1H, J=8.4 Hz), 7.17 (d, 1H, J=8.4 Hz), 7.10 (s, 1H), 6.82 (s, 2H), 5.72 (br s, 1H), 3.23 (m, 2H), 2.92 (m, 2H), 2.1-2.29 (m, 4H), 1.62-1.75 (m, 4H); Mass spectrum (ESI, m/z): Calcd. for C19H21N5O3S, 400.1 (M+H), found 400.1.